Schizoaffective Disorder Market Report 2026

The schizoaffective disorder market size has grown strongly in recent years. It will grow from $7.74 billion in 2025 to $8.14 billion in 2026 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to long-term reliance on antipsychotic medications, increasing diagnosis of schizophrenia spectrum disorders, growing awareness of severe mental illnesses, expansion of psychiatric care facilities, gradual improvement in diagnostic criteria and classification.

The schizoaffective disorder market size is expected to see steady growth in the next few years. It will grow to $9.83 billion in 2030 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to development of novel atypical antipsychotics, increasing demand for long-acting formulations, rising healthcare spending on mental health, expansion of community-based mental health programs, growing focus on personalized treatment approaches. Major trends in the forecast period include increasing use of combination therapy with antipsychotics and mood stabilizers, rising adoption of long-acting injectable antipsychotics, growing emphasis on early diagnosis and intervention, increasing incorporation of psychotherapy alongside pharmacological treatment, expanding use of digital mental health support tools.

The increasing prevalence of neurological disorders is expected to drive the growth of the schizoaffective disorder market in the coming years. Neurological disorders are conditions that impact the nervous system - including the brain, spinal cord, and nerves - resulting in various cognitive, motor, and sensory impairments. Factors contributing to the rise of neurological disorders include genetic mutations, infections, traumatic injuries, environmental toxins, autoimmune responses, and degenerative processes affecting the nervous system. The growing prevalence of these disorders contributes to higher detection and incidence of schizoaffective disorder through shared biological mechanisms, improved diagnostic capabilities, and increased awareness. For example, in April 2023, the National Library of Medicine, a US-based medical research library, reported that approximately 6.7 million Americans were affected by Alzheimer’s disease in 2023, with projections indicating this number could rise to 13.8 million by 2060. Therefore, the increase in neurological disorders is supporting growth in the schizoaffective disorder market.

Key companies in the schizoaffective disorder market are focusing on developing innovative medications, such as extended-release injectable suspension drugs, to improve treatment outcomes, enhance patient adherence, and reduce dosing frequency. Extended-release injectable suspension drugs are formulated to release their active ingredients gradually over a prolonged period, allowing for less frequent dosing compared to traditional immediate-release medications, which improves convenience and compliance. For instance, in July 2024, Luye Pharma Group Ltd., a China-based pharmaceutical company, announced that the US FDA approved ERZOFRI (paliperidone palmitate) extended-release injectable suspension for the treatment of schizophrenia and schizoaffective disorder. This long-acting formulation provides consistent therapeutic effects over time, reducing the frequency of administration and helping to improve patient adherence, lower relapse risk, and enhance quality of life for individuals with chronic mental health conditions.

In March 2024, Bristol Myers Squibb, a US-based biopharmaceutical company, acquired Karuna Therapeutics Inc. for an undisclosed amount. Through this acquisition, Bristol Myers Squibb aims to expand its neuroscience portfolio by incorporating Karuna Therapeutics’ innovative schizophrenia treatment, KarXT, along with its early-stage pipeline. Karuna Therapeutics Inc., based in the US, specializes in developing treatments for psychiatric and neurological disorders, including schizophrenia.

Major companies operating in the schizoaffective disorder market are Pfizer Inc., Johnson & Johnson, Bristol Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Zydus Lifesciences Limited, Neurocrine Biosciences Inc., Alkermes Inc., Luye Pharma Group Ltd., Merz Pharma GmbH & Co. KGaA, Acadia Pharmaceuticals Inc., Intra-Cellular Therapies Inc., Cerevel Therapeutics Inc., Avanir Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Reviva Pharmaceuticals Inc., Zogenix Inc., Sunovion Pharmaceuticals Inc., Newron Pharmaceuticals S.p.A., Sage Therapeutics Inc., Lyndra Therapeutics Inc., BioXcel Therapeutics Inc.

North America was the largest region in the schizoaffective disorder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the schizoaffective disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the schizoaffective disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the schizoaffective disorder market by increasing costs of imported active pharmaceutical ingredients, finished psychiatric drugs, and manufacturing inputs. These impacts are most visible in branded and long-acting injectable medication segments, particularly in north america and europe that rely on global pharmaceutical supply chains.Tariffs are also encouraging domestic drug manufacturing, greater use of generics, and regional supply chain diversification, which may improve long-term treatment availability and cost stability.

The schizoaffective disorder market research report is one of a series of new reports that provides schizoaffective disorder market statistics, including schizoaffective disorder industry global market size, regional shares, competitors with a schizoaffective disorder market share, detailed schizoaffective disorder market segments, market trends and opportunities, and any further data you may need to thrive in the schizoaffective disorder industry. This schizoaffective disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Schizoaffective disorder is a mental health condition characterized by a combination of schizophrenia symptoms, such as delusions or hallucinations, and mood disorder symptoms, including depressive or manic episodes. This long-term condition requires a multidisciplinary treatment approach, combining therapeutic and pharmaceutical interventions to manage its complex nature.

The main drugs used for schizoaffective disorder include antipsychotic medications, mood stabilizers, antidepressants, and anticonvulsants. Antipsychotic medications help control psychotic symptoms, such as hallucinations, delusions, and disorganized thinking. The condition can be influenced by genetic, environmental, and chemical factors. These treatments are administered in hospitals, clinics, and other healthcare settings.

The schizoaffective disorder market consists of revenues earned by entities by providing services such as clinical interviews, psychological assessments, cognitive-behavioral therapy (CBT), interpersonal therapy, and vocational rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The schizoaffective disorder market includes sales of drugs such as risperidone, olanzapine, lithium and valproate, and fluoxetine or sertraline. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.